Author Archives: EpiVax
“Live Fire” Test: Defense Funding for EpiVax Technology
Vaccines on demand? Yes we can. Our team is connected via international teleconferencing to four other academic and biotech company laboratories across the globe, including scientists in Germany and Denmark, a biochemist in Seattle and a vaccine developer at Harvard . . . EpiVax will play a key role in a new “faster, safer” vaccines consortium headed by Mark Poznansky, of MGH/Harvard’s VIC. The consortium is funded by a DARPA (Defense Advanced Research Projects) contract. Proof of principle for this initial project may lead to the development of an approach to create vaccines-on-demand for biodefense. Continue reading
Posted in News
Tagged BIodefense, EpiMatrix, HIV Vaccine, Immunoinformatics, TRIAD, Vaccine
Comments Off
Spring 2012 Immunogenicity Workshop Schedule
Come participate in one of the following hands-on demonstrations of our bioinformatics tools! Each of these workshops features presentations and demonstrations led by our expert immunoinformaticians. Learn from the best! Hands-on Workshops! 5th Antibody Generation, Engineering & Design Conference Frankfurt, … Continue reading
Posted in Events, News
Leave a comment
Any Prime-Boost Mix of Injected or Spray Flu Vaccine Shields Toddlers
Broadest Immune Response from Nasal Spray Vaccine, NIH-Funded Study Finds (The following is an excerpt from an article published by the National Institute of Allergy and Infectious Diseases on August 16, 2011. Featured in the article is Dr. Daniel Hoft, who … Continue reading
Posted in News
Leave a comment
The end of AIDS and Balm in Gilead
What do “love gloves” and a little blue pill have in common? They prevent HIV transmission, and now at least one has the blessing of the Pope! Love gloves is just another word for condoms, and the pill in question is Truvada. These two interventions, combined (when used appropriately), may bring a significant reduction in transmission of HIV around the world, and will be of enormous value because they are cheap, safe, and effective and can be used at the time of ‘risky behavior’ by persons who know that they are about to take a risk. Continue reading
Posted in Blog
Leave a comment
The Thin Red Line
This post is by John Rozehnal and Lauren Levitz – Volunteers HIV vaccine research at the GAIA Vaccine Foundation project in Mali, West Africa. . . . In conducting HIV vaccine research in Bamako, as with any other task, there are fast days and there are slow days. On slow days, we volunteer at the local health clinic, where Lauren works with the midwives in the maternity ward and John performs tests in the clinic’s humble diagnostic lab. One of the most common diagnostic procedures is providing HIV tests to pregnant women. It is staggeringly easy to prevent transmission from mother to child, and doing so is the kind of high-yield intervention that many clinics, ours included, focus their resources on. Our clinic in particular has become a model that the Malian Ministry of Health is looking to bring to scale. Continue reading
Posted in Blog
Tagged GAIA Vaccine Foundation, HIV testing, HIV Vaccine, Mali, West Africa
Leave a comment
EpiVax Receives 4th Highest Federal Grant for Healthcare Therapies in the State
As part of the Therapeutic Discovery Program included in the Affordable Care Act, EpiVax has been awarded two federal grants totaling $252,722. The U.S. Department of Health and Human Services and the U.S. Treasury has awarded a total of $4.6 … Continue reading
Posted in News
Leave a comment
Anne De Groot and Her Work at EpiVax Featured in Smith Alumnae Quarterly
Annie De Groot [class of] ’78 is using mathematical models and cutting-edge computer science to map the body’s response to disease. Her goal is to eradicate some of the world’s deadliest illnesses by making vaccines—and health care— available to everyone. … Continue reading
Posted in News
Leave a comment
EpiVax Awarded Additional NIH Funds for anti-Dec205 Project
This year, EpiVax was awarded $243,561 in Total Direct and Indirect Funding to support the development of their unique HIV vaccine platform (de-tolerized anti-Dec205). The total amount awarded to date is $797,855 in Direct and Indirect costs, to further this … Continue reading
Posted in News
Leave a comment
EpiVax Technology Lands $511K Grant to Expand Research on Vaccines for Neglected Tropical Diseases
PROVIDENCE, R.I. – September 21, 2010 – Adding to a $13 million grant awarded to her Institute for Immunology and Informatics last summer, EpiVax CEO Annie De Groot has received an additional $511,121 from the National Institutes of Health to … Continue reading
Posted in News
Leave a comment
URI Accepting Fellows for NTD Vaccine Design Toolkit and Training Workshop Set for January
PROVIDENCE, R.I. – September 21, 2010 – The University of Rhode Island’s Institute for Immunology and Informatics is currently accepting fellows to participate in a workshop and training course targeting neglected tropical diseases. The workshop will focus on training NTD … Continue reading
Posted in News
Leave a comment
